Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Yakubov

Interventional Cardiology Columbus, OH Medical Doctor

NPI 1316942782 CMS profile 241445

3705 Olentangy River Rd, Ste 100, Columbus, OH 43214

Open in the dashboard

General payments

$906,520

1,661 records reported · program years 2019–2025

Research payments

$83,266

Paid to them · 61 records reported · program years 2019–2025

Ownership & investment interest

$35,998

1 holding reported · through program year 2025

Research they led as principal investigator

$2,322,024 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Steven Yakubov of Columbus, OH is reported in the CMS Open Payments database as having received $906,520 across 1,661 general payments and $83,266 in research payments paid to them. Separately, studies naming them as principal investigator received $2,322,024 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $35,998 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $102,360 217
2024 General $152,756 321
2024 Research $28,822 10
2023 General $159,354 317
2023 Research $17,244 14
2022 General $139,229 333
2022 Research $12,775 14
2021 General $74,368 130
2021 Research $6,075 10
2020 General $149,287 93
2020 Research $6,900 11
2019 General $129,166 250
2019 Research $11,450 2
2019 Ownership $35,998 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Yakubov
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Steven Yakubov were reported at $102,360. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Steven Yakubov Interventional Cardiology median Middle half National median
2019 $129,166 $1,097 $329–$3,048 $163
2020 $149,287 $473 $161–$1,480 $114
2021 $74,368 $677 $233–$1,827 $132
2022 $139,229 $978 $333–$2,724 $149
2023 $159,354 $1,136 $382–$2,986 $160
2024 $152,756 $1,181 $395–$3,326 $164
2025 $102,360 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $318,781 881 payments
  2. Janssen Pharmaceuticals, Inc $140,820 106 payments
  3. Boston Scientific Corporation $134,587 162 payments
  4. Medtronic Vascular, Inc. $96,369 205 payments
  5. Atricure, Inc. $61,339 16 payments
  6. Anika Therapeutics, Inc. $50,673 4 payments
  7. ZOLL Circulation Inc $33,517 29 payments
  8. Amplitude Vascular Systems, Inc. $17,259 2 payments
  9. Occlutech US LLC $12,000 1 payment
  10. Biotronik Inc. $10,863 86 payments
  11. Other $30,312 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $441,946 176 payments
  2. Consulting Fee $267,741 96 payments
  3. Travel and Lodging $72,450 315 payments
  4. Food and Beverage $48,057 1,053 payments
  5. Current or prospective ownership or investment interest $41,202 3 payments
  6. Grant $13,856 2 payments
  7. Acquisitions $9,471 1 payment
  8. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $7,600 4 payments
  9. Compensation for serving as faculty or as a speaker for a medical education program $2,500 2 payments
  10. Honoraria $1,000 1 payment
  11. Other $696 8 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $258,228 648 payments
  2. XARELTO $140,820 106 payments
  3. CoreValve Evolut Transcatheter Valve Systems $73,839 135 payments
  4. LARIAT SUTURE DELIVERY DEVICE $60,121 14 payments
  5. TherOx DS2 Console $20,792 24 payments
  6. Downstream Cartridge $20,792 24 payments
  7. Catheter $20,792 24 payments
  8. General - Therapies $18,075 20 payments
  9. CoreValve Evolut Transcatheter Valve Systems $17,068 47 payments
  10. Resolute $14,424 20 payments
  11. Other $122,999 505 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $64,916 48 payments
  2. Medtronic Vascular, Inc. $13,350 12 payments
  3. Atricure, Inc. $5,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,249

Median for Cardiology: 2,533

Drug cost

$80,268

Median for Cardiology: $485,213

Branded share of claims

24.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 51 $50,121
Xarelto Rivaroxaban Brand 20 $18,868
Atorvastatin Calcium Generic 256 $2,380
Ranolazine Er Ranolazine Brand 20 $2,357
Clopidogrel Clopidogrel Bisulfate Brand 164 $1,444
Metoprolol Succinate Generic 140 $1,243
Losartan Potassium Generic 155 $795
Rosuvastatin Calcium Generic 71 $643
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 55 $632
Amlodipine Besylate Generic 79 $345

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$138,016

Medicare's payments for the services billed

Medicare patients

876

Average age 76

Services billed

1,594

343 women, 533 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 67%
Arthritis 53%
Heart failure 37%
Diabetes 36%
Atrial fibrillation 35%
Chronic kidney disease 34%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$4,675 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,722 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record